

proliferative peptides, methods for making such compounds, and methods for using these compounds for the treatment of hyper-proliferative diseases such as cancer or psoriasis. A current limitation on cancer therapy is that therapeutic agents may not target tumor cells specifically or enter the cells efficiently. A strategy that combines the therapeutic agent with a moiety that mediates cellular entry is one method to overcome this limitation. However, the efficacy of the therapeutic agent within the cells can be reduced by the linkage to the moiety that mediates cellular entry. The compounds of the current invention are designed to enter cells efficiently, and upon entry, to uncouple the therapeutic agent from the cellular targeting moiety.

Rottlerin, a protein kinase C inhibitor, selectively induces apoptosis of metastasized melanoma cells of epithelial morphology (DHHS Ref. No. E-311-2003), and is a potential therapeutic agent. Peptides derived from the known tumor suppressor genes H-Ha-Rev107 and H-TIG3, that are homologous to a peptide of LRAT (lecithin:retinol acyl transferase) cross the cell membrane and localize to the nucleus. These peptides, which inhibit the growth of melanoma cells (described in DHHS Ref. No. E-052-2002), could also serve as intracellular delivery agents.

The current invention discloses a novel composition of rottlerin and LRAT peptide (named LRATlerin). LRATlerin is designed so that the LRAT peptide can release the rottlerin upon cellular entry. LRATlerin has enhanced properties not exhibited by rottlerin or the peptide alone including the ability to induce apoptosis of primary site and metastasized tumor cells that are epithelioid or fibroblastoid, without apparent toxicity normal healthy cells. Thus, the compositions of the current invention have the potential to be highly effective therapies for proliferative diseases.

#### **Modulating Expression of the Metastasis Suppressor MxA**

Jane B. Trepel et al. (NCI)  
DHHS Reference No. E-257-2004/0-US-01 (U.S. Provisional Patent Application)

*Licensing Contact:* Mojdeh Bahar; 301/435-2950; [baharm@mail.nih.gov](mailto:baharm@mail.nih.gov).

The invention discloses compounds that could be used to inhibit metastases. The compounds of the current invention were discovered by high-throughput screening of a novel cell line engineered with a MxA reporter. The compounds could be used to treat metastatic cancers

including prostate and melanomas by increasing MxA expression.

MxA expression reduces cell motility and metastases in a mouse model. Cells expressing MxA produced smaller tumors in engrafted mice compared to controls. When injected into mouse spleens, cells expressing MxA showed a significantly delayed metastasis, and the mice survived significantly longer than controls. Expression of MxA reduced cellular motility of prostate cancer cell lines *in vitro* and reduced cellular motility and invasiveness of the highly metastatic melanoma cell line LOX.

Background information for this technology can be found in DHHS Reference No. E-292-2001.

In addition to licensing, the technology is available for further development through collaborative research with the inventors via a Cooperative Research and Development Agreement (CRADA).

#### **Modified Myelin Basic Protein Molecules**

Michael J. Lenardo et al. (NIAID)  
DHHS Ref. No. E-033-1996/0-US-01  
*Licensing Contact:* Mojdeh Bahar; 301/435-2950; [baharm@mail.nih.gov](mailto:baharm@mail.nih.gov).

This invention is directed to compositions and methods for clinical assessment, diagnosis and treatment of Multiple Sclerosis (MS). The compositions are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein (MBP), and include nucleic acids and polypeptides. The nucleic acids are useful in the efficient production of modified and unmodified MBP polypeptides and the polypeptides are useful for assaying T cells for responsiveness to MBP epitopes. They are further useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating MS.

#### **Modified Proteolipid Protein Molecules**

Michael J. Lenardo et al. (NIAID)  
DHHS Ref. No. E-128-1996/1-US-01  
*Licensing Contact:* Mojdeh Bahar; 301/435-2950; [baharm@mail.nih.gov](mailto:baharm@mail.nih.gov).

This invention is directed to compositions and methods for clinical assessment, diagnosis and treatment of Multiple Sclerosis (MS). The compositions are molecules related to the human proteolipid protein (PLP), and include nucleic acids and polypeptides. The nucleic acids are useful in the production of modified PLP polypeptides and the polypeptides are useful for assaying T cells for responsiveness to PLP epitopes. They are further useful as therapeutic agents that act by inducing T cell responses,

including apoptosis, as a means of treating MS.

Dated: December 15, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-28068 Filed 12-22-04; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HOMELAND SECURITY**

### **Bureau of Customs and Border Protection**

#### **Proposed Collection; Comment Request Certificate of Compliance for Turbine Fuel Withdrawals**

**ACTION:** Notice and request for comments.

**SUMMARY:** As part of its continuing effort to reduce paperwork and respondent burden, Bureau of Customs and Border Protection (CBP) invites the general public and other Federal agencies to comment on an information collection requirement concerning the Certificate of Compliance for Turbine Fuel Withdrawals. This request for comment is being made pursuant to the Paperwork Reduction Act of 1995 (Pub. L. 104-13; 44 U.S.C. 3505(c)(2)).

**DATES:** Written comments should be received on or before February 22, 2005, to be assured of consideration.

**ADDRESSES:** Direct all written comments to Bureau of Customs and Border Protection, Information Services Group, Attn.: Tracey Denning, 1300 Pennsylvania Avenue, NW., Room 3.2C Washington, DC 20229.

**FOR FURTHER INFORMATION CONTACT:** Requests for additional information should be directed to Bureau of Customs and Border Protection, Attn. Tracey Denning, 1300 Pennsylvania Avenue NW., Room 3.2C, Washington, DC 20229, Tel. (202) 344-1429.

**SUPPLEMENTARY INFORMATION:** CBP invites the general public and other Federal agencies to comment on proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (Pub. L. 104-13; 44 U.S.C. 3505(c)(2)). The comments should address: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimates of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity

of the information to be collected; (d) ways to minimize the burden including the use of automated collection techniques or the use of other forms of information technology; and (e) estimates of capital or start-up costs and costs of operations, maintenance, and purchase of services to provide information. The comments that are submitted will be summarized and included in the CBP request for Office of Management and Budget (OMB) approval. All comments will become a matter of public record. In this document CBP is soliciting comments concerning the following information collection:

*Title:* Certificate of Compliance for Turbine Fuel Withdrawals.

*OMB Number:* 1651-0072.

*Form Number:* N/A.

*Abstract:* This information is collected to ensure regulatory compliance for Turbine Fuel Withdrawals to protect revenue collections.

*Current Actions:* There are no changes to the information collection. This submission is being submitted to extend the expiration date.

*Type of Review:* Extension.

*Affected Public:* Businesses, Institutions.

*Estimated Number of Respondents:* 30.

*Estimated Time Per Respondent:* 12 hours.

*Estimated Total Annual Burden Hours:* 360.

*Estimated Total Annualized Cost on the Public:* \$14,916.

Dated: December 16, 2004.

**Tracey Denning,**

*Agency Clearance Officer, Information Services Branch.*

[FR Doc. 04-28069 Filed 12-22-04; 8:45 am]

**BILLING CODE 4820-02-P**

## DEPARTMENT OF HOMELAND SECURITY

### Bureau of Customs and Border Protection

#### Proposed Collection; Comment Request; Request for Information

**ACTION:** Notice and request for comments.

**SUMMARY:** As part of its continuing effort to reduce paperwork and respondent burden, the Bureau of Customs and Border Protection (CBP) invites the general public and other Federal agencies to comment on an information collection requirement concerning Request for Information. This request for

comment is being made pursuant to the Paperwork Reduction Act of 1995 (Pub. L. 104-13; 44 U.S.C. 3505(c)(2)).

**DATES:** Written comments should be received on or before February 22, 2005, to be assured of consideration.

**ADDRESSES:** Direct all written comments to Bureau of Customs and Border Protection, Information Services Group, Attn.: Tracey Denning, 1300 Pennsylvania Avenue, NW., Room 3.2C, Washington, DC 20229.

**FOR FURTHER INFORMATION CONTACT:**

Requests for additional information should be directed to Bureau of Customs and Border Protection, Attn.: Tracey Denning, 1300 Pennsylvania Avenue NW., Room 3.2C, Washington, DC 20229, Tel. (202) 344-1429.

**SUPPLEMENTARY INFORMATION:** CBP invites the general public and other Federal agencies to comment on proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (Pub. L. 104-13; 44 U.S.C. 3505(c)(2)). The comments should address: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimates of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden including the use of automated collection techniques or the use of other forms of information technology; and (e) estimates of capital or start-up costs and costs of operations, maintenance, and purchase of services to provide information. The comments that are submitted will be summarized and included in the CBP request for Office of Management and Budget (OMB) approval. All comments will become a matter of public record. In this document CBP is soliciting comments concerning the following information collection:

*Title:* Request for Information.

*OMB Number:* 1651-0023.

*Form Number:* Form CBP-28.

*Abstract:* Form CBP-28 is used by CBP personnel to request additional information from importers when the invoice or other documentation provide insufficient information for CBP to carry out its responsibilities to protect revenues.

*Current Actions:* There are no changes to the information collection. This submission is being submitted to extend the expiration date.

*Type of Review:* Extension.

*Affected Public:* Businesses, Individuals, Institutions.

*Estimated Number of Respondents:* 60,000.

*Estimated Time Per Respondent:* 1 hour.

*Estimated Total Annual Burden*

*Hours:* 60,000.

*Estimated Total Annualized Cost on the Public:* N/A.

Dated: December 16, 2004.

**Tracey Denning,**

*Agency Clearance Officer, Information Services Group.*

[FR Doc. 04-28070 Filed 12-22-04; 8:45 am]

**BILLING CODE 4820-02-P**

## DEPARTMENT OF HOMELAND SECURITY

### Bureau of Customs and Border Protection

#### Proposed Collection; Comment Request; Establishment of a Container Station

**ACTION:** Notice and request for comments.

**SUMMARY:** As part of its continuing effort to reduce paperwork and respondent burden, Bureau of Customs and Border Protection (CBP) invites the general public and other Federal agencies to comment on an information collection requirement concerning Establishment of a Container Station. This request for comment is being made pursuant to the Paperwork Reduction Act of 1995 (Pub. L. 104-13; 44 U.S.C. 3505(c)(2)).

**DATES:** Written comments should be received on or before February 22, 2005, to be assured of consideration.

**ADDRESSES:** Direct all written comments to Bureau of Customs and Border Protection, Information Services Group, Attn.: Tracey Denning, 1300 Pennsylvania Avenue, NW., Room 3.2C, Washington, DC 20229.

**FOR FURTHER INFORMATION CONTACT:**

Requests for additional information should be directed to Bureau of Customs and Border Protection, Attn.: Tracey Denning, 1300 Pennsylvania Avenue NW., Room 3.2C, Washington, DC 20229, Tel. (202) 344-1429.

**SUPPLEMENTARY INFORMATION:** CBP invites the general public and other Federal agencies to comment on proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (Pub. L. 104-13; 44 U.S.C. 3505(c)(2)). The comments should address: (a) Whether the collection of information is necessary for the proper performance of the